XM does not provide services to residents of the United States of America.

U.S. STOCKS Nike, Battalion Oil, gold miners



<html xmlns="http://www.w3.org/1999/xhtml"><head><title>BUZZ-U.S. STOCKS ON THE MOVE-Nike, Battalion Oil, gold miners</title></head><body>

Eikon search string for individual stock moves: STXBZ

The Day Ahead newsletter: https://refini.tv/3LI4BU7

The Morning News Call newsletter: https://refini.tv/3dKUyB8

U.S. stock index futures edged lower on Friday, taking a pause from the previous session's rally that set Wall Street's main indexes on track for weekly gains after the Federal Reserve took a pivotal stance on monetary policy earlier in the week. .N


At 8:12 ET, Dow e-minis 1YMc1 were down 0.04% at 42,041. S&P 500 e-minis ESc1 were down 0.15% at 5,709.25, while Nasdaq 100 e-minis NQc1 were down 0.20% at 19,810.

The top three NYSE percentage gainers premarket .PRPG.NQ:
** Surf Air Mobility SRFM.N, up 9.7%
** Oklo Inc OKLO.N, up 9.2%
** Culp CULP.N, up 8.7%

The top three NYSE percentage losers premarket .PRPL.NQ:
** Fedex FDX.N, down 13.3%
** Bright Horizons Family Solutions BFAM.N, down 11%
** Olo OLO.N, down 10.5%

The top two Nasdaq percentage gainers premarket .PRPG.O:
** Expion360 XPON.O, up 107.9%
** Banzai International BNZI.O, up 95.8%

** Nike NKE.N: up 7.6% premarket
BUZZ - Rises as veteran Elliot Hill to take helm as CEO nL4N3L20SC

** Newmont NEM.N: up 1.5% premarket

** Barrick Gold GOLD.N: up 1.8% premarket ** Gold Fields GFI.N: up 3.1% premarket ** Harmony Gold Mining HMY.N: up 2.7% premarket
BUZZ - Gold miners rise as bullion hits record high of $2,600/oz nL4N3L20UI


** Fedex FDX.N: down 13.3% premarket
BUZZ - Shares down after dour Q1 earnings nL4N3L20VW


** Rapid7 RPD.O: down 2.2% premarket
BUZZ - RBC downgrades Rapid7 to 'sector perform' nL4N3L20X7


** Battalion Oil BATL.N: up 119.4% premarket
BUZZ - Rises on new merger deal with Fury Resources nL4N3L20W0


** Apellis Pharmaceuticals APLS.O: down 7.2% premarket
BUZZ - Falls as EU panel confirms negative opinion for eye disease drug nL4N3L20WI


(Compiled by Neil J Kanatt and Rajarshi Roy)

</body></html>

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.